Piotr Klimiuk

Prof., MD, PhD

Medical University of Bialystok

Poland

Research Interests

Explore related searches

Professors in Poland

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Prof. Piotr Klimiuk, MD, PhD, is a distinguished faculty member at the Medical University of Bialystok in Poland. His research primarily focuses on rheumatology, specifically the efficacy and safety of biosimilars in the treatment of rheumatoid arthritis and psoriatic arthritis. Recent studies led by Prof. Klimiuk have explored the outcomes of various treatment approaches, including tyrosine kinase inhibition and self-administration of biosimilars.

Articles (5)

Year:

2025

Year:

2025

Year:

2024

Year:

2022

Year:

2021

Collaborators (4)

Gerd-Rüdiger Burmester

Senior Professor

Charité - Universitätsmedizin Berlin

GERMANY

View details

Arthur Kavanaugh

professor

University of California, San Diego

UNITED STATES

View details

Piotr Wiland

Wroclaw Medical University

POLAND

View details

Daniel E. Furst

University of California

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Piotr Klimiuk

Research Interests

Explore related searches

Contact this professor

About

Articles (5)

Highly selective tyrosine kinase 2 inhibition with zasocitinib (TAK-279) improves outcomes in patients with active psoriatic arthritis: a randomised phase 2b study

Usability, efficacy, and safety of candidate tocilizumab biosimilar CT-P47 self-administration via auto-injector and pre-filled syringe in patients with rheumatoid arthritis: a single-arm, open-label, phase 3 study

Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks of switching data from reference tocilizumab to CT-P47

Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomized, double-blind study in rheumatoid arthritis

Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study

Collaborators (4)

Gerd-Rüdiger Burmester

Arthur Kavanaugh

Piotr Wiland

Daniel E. Furst

Make your next move.